Ubs Group Ag Cardiol Therapeutics Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRDL
# of Institutions
45Shares Held
5.07MCall Options Held
5.2KPut Options Held
9.5K-
Tejara Capital LTD London, X01.77MShares$2.32 Million1.67% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD1.17MShares$1.53 Million0.46% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$1.04 Million0.36% of portfolio
-
Lion Street Advisors, LLC273KShares$357,9980.19% of portfolio
-
Foundations Investment Advisors, LLC162KShares$212,1540.01% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $81.1M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...